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ABSTRACT 
A method has been developed for metabolite profiling of the salivary metabonome based on 
protein precipitation and ultra-high performance liquid chromatography coupled with ion 
mobility-mass spectrometry (UHPLC-IM-MS). The developed method requires 0.5 mL of 
human saliva, which is easily obtainable by passive drool. Standard protocols have been 
established for the collection, storage and pre-treatment of saliva. The use of UHPLC allows 
rapid global metabolic profiling for biomarker discovery with a cycle time of 15 minutes. 
Mass spectrometry imparts the ability to analyse a diverse number of species reproducibly 
over a wide dynamic range, which is essential for profiling of biofluids. The combination of 
UHPLC with IM-MS provides an added dimension enabling complex metabolic samples to 
be separated on the basis of retention time, ion mobility and mass-to-charge ratio in a single 
chromatographic run. The developed method has been applied to targeted metabolite 
identification and untargeted metabolite profiling of saliva samples collected before and after 
exercise-induced physiological stress. δ-Valerolactam has been identified as a potential 
biomarker on the basis of retention time, MS/MS spectrum and ion mobility drift time. 
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1. INTRODUCTION 
Human saliva is a complex biofluid composed of secretions from major and minor salivary 
glands, gingival crevicular fluid, oral bacteria and food debris. Saliva ensures the stability in 
the oral cavity and aids in functions such as lubrication, speech, digestion, antibacterial 
activity, maintaining integrity of tooth enamel and sense of taste. Whole saliva consists of a 
variety of biologically relevant compounds including hormones, nucleic acids, peptides, 
proteins, metabolites, immunoglobulins, enzymes (lysozymes, lingual lipase, α-amylase etc.), 
mucins, electrolytes (Na, K, Ca, Mg, carbonates, phosphates etc.) and nitrogenous products 
such as urea and ammonia (Humphrey and Williamson, 2001). Saliva is a highly variable and 
individualised fluid and it’s composition and flow is affected by various factors including age, 
gender, circadian rhythm, circannual cycle, psycho-emotional state, physical exercise, 
hydration, systemic diseases, medication and nutrition. (De Almeida et al., 2008).  
In the past, saliva or oral fluid has been neglected as a diagnostic medium and preference has 
been given to other more invasively collected biofluids such as blood, serum and plasma. 
Saliva has the advantage of allowing non-invasive sample collection and substances present 
in saliva are in their biologically active form (Pink et al., 2009). The pace of research into 
saliva as a diagnostic medium has accelerated in recent years with the advent of new 
techniques, which have provided a wealth of information regarding the biochemical and 
physicochemical properties of saliva. The applications of saliva as a diagnostic medium have 
been summarised elsewhere and the potential for early detection of systemic diseases or 
exposure to harmful substances has been demonstrated (Pink et al., 2009; Walsh, 2007). The 
complexity, biological significance of saliva and the advancements in analytical technology 
have shown the immense potential of this matrix in metabolite profiling. 
Metabolic profiling, sometimes described as metabonomics or metabolomics, refers to the 
targeted or global assessment of endogenous small-molecule metabolites within a biological 
system. The term metabonomics was coined by Nicholson et al. and defined as “the 
quantitative measurement of the dynamic multiparametric response of a living system to 
pathophysiological stimuli or genetic modification” (Lindon and Nicholson, 2008; Nicholson 
et al., 1999). The metabolome is regarded as the most predictive phenotype and hence the 
study of metabolites has been acknowledged as a desirable tool for monitoring the biological 
state of organisms and for disease diagnosis (Zhang et al., 2012). Metabolite profiling is a 
technologically driven science and has made significant progress with the advancement of 
separation science (Issaq et al., 2008; Xiayan and Legido-Quigley, 2008), with the majority 
of applications centred around global profiling and biomarker detection in biofluids, such as 
whole blood, serum, plasma, urine, cerebrospinal fluid, synovial fluid, semen etc. (Zhang et 
al., 2012). Untargeted metabolic profiling of saliva using NMR and LC-MS has shown 
promise (Aimetti et al., 2011; Álvarez-Sánchez et al., 2012; Takeda et al., 2009; Wei et al., 
2010). Liquid chromatography-mass spectrometry (LC-MS) is a widely used technique for 
the targeted and non-targeted, global metabolic profiling of low molecular mass metabolites 
and other compounds in biofluids. However, the use of this technique for metabolite profiling 
of saliva remains under explored.  
Ion mobility spectrometry is a technique which separates ionised molecules on the basis of 
their collision cross sections (i.e. size and shape) in the gas phase and has been extensively 
reviewed (Creaser et al., 2004; Kanu et al., 2008). The application of ion mobility 
spectrometry hyphenated with mass spectrometry (IM-MS) to metabolite profiling has been 
reported (Dwivedi et al., 2007; Harry et al., 2008), but the use of on mobility-mass 
spectrometry combined with ultra-high performance liquid chromatography (Swartz, 2005) 
has not been explored.  
This study describes the development and validation of a method for the targeted and 
untargeted metabolic profiling of saliva by ultra-high performance liquid chromatography-ion 
mobility-mass spectrometry (UHPLC-IM-MS). The method has been applied to the profiling 
of metabolites and the discovery of potential discriminating biomarker ions of exercise-
induced physiological stress. 
  
  
2. EXPERIMENTAL 
2.1 Chemicals and reagents 
Acetonitrile (analytical grade), water (analytical grade) and formic acid (>99.9%) were 
obtained from ThermoFisher Scientific (Loughborough, UK). L-carnitine (>99%) and 
hydrocortisone (>99%) were obtained from Sigma-Aldrich (Gillingham, UK). A 400 ng/mL 
stock solution of leucine enkephalin was obtained from Waters Corporation (Manchester, UK) 
and used to prepare a 2 ng/mL working solution of leucine enkephalin in water:acetonitrile 
(50:50) (v/v) as a LockMass (m/z 556.2771) solution. A standard mixture of 0.01 mg/mL L-
carnitine and hydrocortisone was prepared in water:acetonitrile (95:05) (v/v) with 0.1% 
formic acid. A standard solution of 0.01 mg/mL L-phenylalanine was prepared in 
water:acetonitrile (95:05) (v/v) with 0.1% formic acid. 
2.2 Sampling and storage 
Sampling of saliva for this study was carried out under the ethical approval obtained from the 
local ethical advisory committee (Ethical Advisory Committee, Loughborough University, 
Loughborough, LE11 3TU) with reference number G10-P24. Participants were healthy, non-
smoking males, aged 18-35 and were recruited from Loughborough University staff and 
students (n=10). 
Saliva was collected by passive drool from participants after an overnight fast. Participants 
were seated with their head tilted forward, allowing saliva to pool in front of the mouth. 
Saliva was allowed to be dribbled out of the mouth into a glass collection vial (30 mL 
Chromacol, UK) at regular intervals. This process was repeated until sufficient amount of 
saliva (i.e. 1 mL) was obtained (Chiappin et al., 2007). Saliva collected from all the 
participants was re-aliquoted as 500 μL aliquots into microcentrifuge tubes (2.0 mL, LoBind 
Eppendorf, UK). 500 μL saliva from all the participants was pooled together and re-aliquoted 
as 500 μL aliquots to be used for method development and quality control (QC). Samples 
were aliquoted prior to storage to minimise freeze-thaw cycles. The saliva samples were 
stored at -80°C immediately after aliquoting to arrest biological activity.  
2.3 Sample pre-treatment 
Saliva samples stored at -80°C were thawed at room temperature for 30 minutes prior to 
sample clean-up by protein precipitation. Each thawed saliva sample was vortexed for 30 
seconds followed by ultra-sonication for 1 minute to breakdown mucous substances in saliva 
and to improve homogeneity. Protein precipitation was achieved by the addition of 1 mL 
acetonitrile to 500 μL of saliva i.e. 2:1 ratio of precipitant to saliva (Polson et al., 2003). The 
mixture was vortexed for 30 seconds followed by ultra-sonication for 1 minute and then 
subjected to centrifugation at 10,000 g for 10 minutes at ambient temperature. Precipitated 
proteins from the sample were removed as a pellet at the bottom of the microcentrifuge tube. 
The supernatant was transferred to a fresh microcentrifuge tube and evaporated to near 
dryness (~5 µL) using Turbovap LV concentration workstation (Caliper Life Sciences, 
Hopkinton, MA, USA) prior to being reconstituted in 50 μL water/acetonitrile (95:05) (v/v) 
with 0.1% formic acid. The reconstituted saliva extract was placed in a 200 μL polypropylene 
micro-insert (Supelco, UK) in an autosampler vial (2 mL) for UHPLC-IM-MS analysis. 
2.4 Method development 
2.4.1 Instrumentation 
The liquid chromatographic separations were performed on a Waters ACQUITY UPLC 
chromatograph with an in-built auto-sampler (Waters Corporation, Manchester, UK) fitted 
with a Waters ACQUITY BEH (bridged ethylene hybrid) C18 column (2.1 mm x 100 mm, 
1.7 μm; Waters Corporation, Manchester, UK) maintained at 40°C. A VanGuard BEH C18 
pre-column (Waters Corporation, Manchester, UK) was attached in series with the analytical 
column. The UPLC system was coupled with a Waters Synapt HDMS ion-mobility mass 
spectrometer (Waters Corporation, Manchester, UK). MassLynx 4.1 (Waters Corporation, 
Manchester, UK) was used for controlling the setup and for data acquisition. A Waters 
ACQUITY UPLC chromatograph (Waters Corporation, Manchester, UK) coupled with a 
LTQ Orbitrap Mass Spectrometer (ThermoFisher Scientific, UK) was used to acquire 
accurate mass measurements on discriminant metabolites. 
2.4.2 UHPLC conditions 
Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 0.1% 
formic acid in acetonitrile (v/v). The chromatographic gradient programme was optimised 
using a solution of L-carnitine and hydrocortisone (0.01 mg/mL). The mobile phase flow rate 
was set to 0.5 mL/min. The saliva extract (10 μL injected) was analysed by the optimised 
chromatographic gradient: 5% B (0-1 min), increased to 35% B (1-10 min). This was 
followed by a column clean-up phase built into the method to reduce carry over and condition 
the column for analysis of subsequent samples, in which the mobile phase was increased to 
95% B (10-11 min) and maintained at 95% B (11-12 min) before returning to initial 
conditions (13-15 min). 
2.4.3 MS conditions 
Electrospray ionisation conditions for the Synapt HDMS, with the ion source operated in 
positive ion mode were: capillary voltage 3.0 kV; cone voltage 30 V; source temperature 
120°C; desolvation temperature 300°C; desolvation gas, N2 gas flow 600 L/hr; cone gas flow 
30 L/hr. Mass spectra were acquired with a scan rate of 1 sec/scan with a 0.02 sec inter-scan 
delay. Conditions for LTQ-Orbitrap MS were: heated electrospray ionisation (HESI) source 
operated under positive polarity mode; source voltage 4.5 kV; capillary voltage 35V; 
capillary temperature 300ºC and sheath gas flow 45 L/hr. 
2.4.4 Optimisation of the ion-mobility separation 
The tri-wave (T-wave) drift cell conditions were set at 30 mL/min drift gas (N2) with a 
variable travelling wave height ramp of 7.0-15.0 V and wave velocity of 300 m/s. The mass 
spectrum acquisition rate was 0.065 ms/scan. Optimisation of tri-wave parameters was 
carried out on-line by directly infusing 2 ng/mL solution of Leucine Enkephalin (data not 
shown). The optimised variable travelling wave height ramp was set to 6.0-13.0 V. Saliva 
extract was analysed prior to and after optimisation of ion-mobility separation. 
2.4.5 Dynamic range determination and reproducibility 
Injection volumes (1-20 µL) of pooled saliva extract were analysed by UHPLC-IM-MS. 
Chromatographic peak areas of selected endogenous metabolite ions eluting at various 
retention times throughout the chromatogram were extracted and plotted against the injection 
volume of saliva.  
The reproducibility of the analytical method was assessed using the optimised injection 
volume (10 µL) determined from the dynamic range experiment. Six pooled saliva extract 
samples were analysed consecutively by UHPLC-IM-MS. Chromatographic retention times 
and chromatographic peak areas of extracted endogenous metabolite ions were used to 
establish the reproducibility of the analytical method. 
2.5 Analysis of before-exercise and after-exercise saliva samples 
Participants exercised for 30 minutes on a cycle ergometer (Lode Corival, Groningen, The 
Netherlands) at a power output of 2 Watts/Kg of body mass of the participant. Two saliva 
samples were collected per participant, one before exercise and the other 30 minutes after the 
end of the exercise. 
2.5.1 Analytical protocol 
A series of five consecutive injections of a pooled saliva extract were run prior to the sample 
analysis to condition the chromatographic column. The analysis of replicate injections 
showed little retention time drift following this conditioning procedure. The sample list was 
randomised using Microsoft Excel prior to analysis and a pooled saliva extract was analysed 
after every 5 saliva samples as a quality control sample (QC). The sensitivity of the 
instrument was monitored on-line using the LockMass signal. A separate method blank study 
was carried out as a part of initial UHPLC-IM_MS method development for this work. 
Method blanks demonstrated no contamination due to polypropylene micro-centrifuge tubes 
or polypropylene micro-inserts used for this study. Method blanks also demonstrated no 
carry-over between saliva sample runs. 
2.5.2 Data mining and multivariate statistical analysis 
Data mining was carried out using MarkerLynx XS (Waters Corporation, Manchester, UK). 
The parameters used were retention time range 0-10 minutes; retention time tolerance was set 
to 0.1 min; mass range 50-500 Da; mass tolerance 0.05 Da; isotopic peaks were excluded for 
analysis; minimum spectral peak intensity was set to 50 counts. The resulting three 
dimensional data matrix containing arbitrarily assigned peak index (consisting of m/z and 
retention time pairs), sample names (observations) and their normalised chromatographic 
peak areas (variables) was exported to SIMCA-P+ (Umetrics, Sweden) for further data 
processing. Data was normalised to the total ion intensity within the particular sample for 
each feature (i.e. m/z_retention-time pair) using MarkerLynx XS (Waters Corporation, 
Manchester, UK) using chromatographic peak area. This method of normalisation adjusts all 
the ion intensities so that the sum of intensities within each sample is the same. Multivariate 
statistical analysis, principal component analysis (PCA) and orthogonal partial least squares 
discriminant analysis (OPLS-DA), were carried out on normalised data to identify 
discriminant metabolites in saliva between the two groups of samples i.e. before and after 
exercise. 
  
  
3. RESULTS AND DISCUSSION 
3.1 Method development 
Protein precipitation was the only sample clean-up procedure applied to the saliva prior to 
UHPLC-IM-MS analysis, in order to minimise the effect of discrimination and the 
unpredictable behaviour of unknown metabolites during sample preparation (Álvarez-
Sánchez et al., 2012). The selection of endogenous metabolites for validating the method 
ensured that the matrix effects were accounted for during data processing. 
[Figure 1] 
 A typical UHPLC-IM-MS profile for a saliva extract is shown in Figure 1 illustrating the 
complexity of the three dimensional nested dataset obtained from the analysis. The two 
dimensional retention time vs ion mobility drift time plot shows multiple species contributing 
to single chromatographic peaks (Figure 1 c), demonstrating that the combination of ion 
mobility with UHPLC allows further separation of co-eluting species. Ion mobility spectrum 
is plotted as bins, where each bin represents an acquired mass spectrum (65 µs/scan), with 
200 bins covering the drift time range of 0-13 ms. Spectra were accumulated to yield 200 
mass spectra and one ion mobility spectrum per second giving 6-7 data points across a typical 
UHPLC peak.  
 The UHPLC chromatographic gradient programme used for the analysis of saliva extract 
was optimised using 0.01 mg/mL solution of L-carnitine and hydrocortisone such that the 
highly polar metabolite, L-carnitine, was slightly retained on the column, whereas low 
polarity hydrocortisone eluted towards the end of the 10 min chromatographic gradient (data 
not shown). The total cycle time was 15 minutes, which is suitable for high throughput global 
metabolic profiling workflows. 
 [Figure 2] 
The major parameters that affect the separation of ions in the T-wave drift cell are IMS gas 
pressure, IMS wave velocity and IMS wave height. The ion mobility separation shown in 
Figure 1 was improved by adjusting the variable wave height ramp as a wave gradient 
effectively increases the length of the IMS drift cell (Shvartsburg and Smith, 2008).  
Figure 2 (a) shows IM separation prior to optimisation, with a wave height ramp of 7.0-15.0 
V. The majority of the components of the saliva extract have a drift time in the first 100 
bins/spectra, associated with IM drift times of <2.6 ms. Ideally, only the first 20 bins/spectra 
and the last 20 bins/spectra should be empty with analytes distributed across the remaining 
bins/spectrum (0.13-11.7 ms) of an overall drift time plot for optimum separation. This can 
be seen in Figure 2 (b), with an optimised wave height ramp of 6.0-13.0 V. Under the 
optimised UHPLC and ion mobility conditions, analytes that are unresolved and co-eluting in 
the retention time dimension may be resolved in the ion mobility dimension as a result of the 
increased peak capacity of UHPLC-IM-MS. 
The effect of UHPLC injection volume was assessed for injection volumes in the range of 1-
20 µL. Four randomly extracted metabolite ions, spread across the chromatographic range 
were selected to assess the dynamic range of the analytical system. Chromatographic peak 
areas showed a linear response for injection volumes in the range 1μL to 10μL, with the 
response levelling out above 15 μL (data shown in supplementary information figure S1). 
Hence, a 10 μL injection volume of saliva extract was used for subsequent analysis and 
global metabolic profiling studies as it lies in the dynamic range of the analytical method. 
The results of a UHPLC reproducibility study (n=6) of peak area and retention time are 
summarised in supplementary information Table T1. Data show less than 9% relative 
standard deviation (RSD) for chromatographic peak areas and less than 1% RSD for retention 
times across the range of the chromatogram. The data show that the method is consistent and 
reliable, which is required for measuring small differences in concentration of detectable 
metabolites in metabolic profiling studies.  
[Figure 3] 
3.2 Targeted metabolite identification 
The nested UHPLC-IM-MS dataset collected from a saliva sample maybe interrogated for the 
presence of a targeted analyte. Figure 3 shows an example of the extracted ion chromatogram 
(figure 3 a) and ion mobility data (figure 3 c) for a targeted analyte, L-phenylalanine present 
in saliva. Both ion mobility and retention times show a close match with a standard indicating 
positive identification of the L-phenylalanine and that matrix effects do not adversely affect 
retention times. The shape of the chromatographic and ion mobility peaks (Figure 3 a and c) 
indicates the presence of a single species. Selection of the appropriate retention time and ion 
mobility region (retention time 1.21 min, ion mobility bin numbers 64-68) for L-
phenylalanine enhances the relative mass spectral response of the protonated amino acid 
(Figure 3 b and d). 
3.3 Global metabolite profiling analysis of before- and after-exercise saliva samples 
The UHPLC-IM-MS analysis of saliva extracts generates a complex dataset consisting of 
mass-to-charge ratio, chromatographic retention time and ion mobility drift time. IM 
separation being orthogonal to that of liquid chromatographic separation and mass-to-charge 
ratio increases the peak capacity as a result of the separation of species of the same m/z or 
retention time in the mobility dimension. The resulting multidimensional UHPLC-IM-MS 
datasets present a challenge for the multivariate statistical techniques commonly employed 
for global metabolite profiling studies. The powerful software available for de-convoluting 
UHPLC-MS data is not equipped to account for ion-mobility dimension while compiling data 
matrix for multivariate analysis. The complexity of the data was therefore reduced in the 
initial stages of the analysis by collapsing the IM dimension.  
[Figure 4] 
Key factors in the analysis of complex biological metabonomic samples include 
chromatographic column conditioning, number of quality control samples and run order 
(Want et al., 2010). These factors were evaluated using pooled saliva samples collected from 
male volunteers before-exercise and after-exercise. Figure 4 (a) shows unsupervised principal 
component analysis (PCA) of all the randomised before-exercise and after-exercise saliva 
samples and replicates of quality control (QC) samples consisting of an extract of a pooled 
saliva sample, which was analysed after every batch of 5 samples. The model was based on a 
total of 4078 variables, which were normalised and Pareto scaled it being the preferred option 
while dealing with metabolomic data obtained by MS (Van den Berg et al., 2006). Clustering 
of quality control (QC) samples (circled in Figure 4 a) provides evidence of consistent and 
reliable data quality adequate for metabolic profiling studies. 
The unsupervised PCA approach indicates partial separation between the two classes of 
samples (Figure 4 a) with before-exercise samples having low principle component 2 (PC2) 
scores while after-exercise samples showing higher PC2 scores. Supervised approaches, such 
as partial least squares (PLS) and orthogonal partial least squares discriminant analysis 
(OPLS-DA) models, are often applied in metabonomics to uncover relationships buried in the 
background of larger inherent effects (Fonville et al., 2010). In biological systems, for 
instance, it is often the case that several factors contribute to the metabolic state of an 
organism e.g. age, gender, nutrition, environment etc. Hence, to focus on the biological 
question of interest, physiological stress in this case, and to disregard other sources of 
variation an OPLS-DA model was used. A total of 3067 normalised, Pareto scaled variables 
were used to construct the model, which was able to distinguish between the two classes of 
samples (Figure 4 b). 
[Figure 5] 
A loadings S-plot was constructed using the OPLS-DA model to segregate discriminant 
metabolites (shown in supplementary information Figure S2). A number of variables were 
selected from extreme ends of the s-plot and their normalised trend plots were compared as 
initial screening for potential biomarker ions (data not shown). Discriminant features were 
extracted from the S-plot and were verified by comparing their extracted ion chromatogram 
(EIC) from raw data. Figure 5 (a) shows an example of the raw data for a selected potential 
biomarker ion (m/z 100.07 ± 0.02 and a retention time of 1.31 min) showing up-regulation of 
this ion with a mean fold change of 15. The retention time and m/z data for this molecule 
were used to extract the selected ion mobility spectrum shown in Figure 5 (b). The single 
symmetrical IM spectrum peak indicates the presence of a single component. Identification of 
this component would therefore require the candidate molecule to match the ion mobility as 
well as the retention time and m/z characteristics. 
[Figure 6] 
Accurate mass measurement data and isotopic ratio data on the discriminant metabolite ion 
were obtained by analysing a pooled saliva extract sample using high resolution mass 
spectrometry. The molecular formula, C5H9NO, was determined from the accurate mass and 
isotopic pattern. The generated molecular formula was used to search electronic sources 
including ChemSpider and the Human Metabolome Database (HMDB) (Wishart et al., 2013) 
for possible candidate metabolites. The number of candidate molecules was reduced by 
application of biological knowledge about the candidate metabolites, such as the biological 
availability of candidate metabolite in human saliva; δ-valerolactam and N-methyl-2-
pyrrollidinone were shortlisted as possible matches. Authentic standards of the shortlist of 
candidate metabolites were analysed using UHPLC-IM-MS and by UHPLC-MS/MS. 
The retention time, MS/MS spectrum and ion mobility drift time of the biomarker ion m/z 
100.07±0.02 in the pooled saliva samples matched that of δ-valerolactam (Figure 6). This 
provides strong evidence for the assignment of this molecule as a potential biomarker of 
exercise induced physiological stress. δ-valerolactam is included in the human metabolome 
database (reference number HMDB11749) as a known metabolite present in saliva (Wishart 
et al., 2013). It has been shown in mouse models to result from the metabolism of cadaverine 
(Callery and Geelhaar, 1984), which is known to be present at part per million levels in 
human saliva as a potential source of δ-valerolactam (Cooke et al., 2003). The physiological 
role of δ-valerolactam is not well understood and the effects of exercise and other stresses on 
its metabolism are at present unknown. 
   
  
4. CONCLUSIONS 
This study demonstrates proof of principle in a pilot study with a small number of 
participants that mass-to-charge and ion mobility data may be acquired within the timescale 
of an UHPLC experiment for metabonomic analysis of saliva. The combination of UHPLC 
with IM-MS provides an added dimension enabling enhanced separation of co-eluting 
components of complex metabonomic samples on the basis of retention time, ion mobility 
and mass-to-charge ratio in a single 10-minute chromatographic run.  
The reported results show the potential of the UHPLC-IM-MS technique for the targeted and 
the global metabolic profiling analysis of saliva and other biological fluids, and for the 
subsequent biomarker discovery process. In this study, δ-valerolactam has been identified as 
a potential biomarker in saliva of exercise-induced physiological stress on the basis of 
retention time, MS/MS spectrum and ion mobility drift time compared to a δ-valerolactam 
standard. The advantages of ion mobility spectrometry with UHPLC-MS for discovery and 
identification of metabolites from metabolite profiling studies have been demonstrated. This 
work demonstrates the potential of hyphenated ion mobility mass spectrometry for non-
hypothesis driven discovery-based metabolomic studies. 
  
5. ACKNOWLEDGEMENTS 
The authors would like to thank Jayne Kirk and Waters Corporation for the help with the 
software. Authors would like to thank Robert Smith for his input to identification of 
metabolite and Daniel Weston at AstraZeneca for providing accurate mass data.   
  
  
6. REFERENCES 
Aimetti, M., Cacciatore, S., Graziano, A., Tenori, L., 2011. Metabonomic analysis of saliva 
reveals generalized chronic periodontitis signature. Metabolomics 8, 465–474. 
Álvarez-Sánchez, B., Priego-Capote, F., Luque de Castro, M.D., 2012. Study of sample 
preparation for metabolomic profiling of human saliva by liquid chromatography-time of 
flight/mass spectrometry. Journal of chromatography. A 1248, 178–81. 
Callery, P.S., Geelhaar, L.A., 1984. Biosynthesis of 5-aminopentanoic acid and 2-piperidone 
from cadaverine and 1-piperideine in mouse. Journal of Neurochemistry 43, 1631–1634. 
Chiappin, S., Antonelli, G., Gatti, R., De Palo, E.F., 2007. Saliva specimen: a new laboratory 
tool for diagnostic and basic investigation. Clinica Chimica Acta 383, 30–40. 
Cooke, M., Leeves, N., White, C., 2003. Time profile of putrescine, cadaverine, indole and 
skatole in human saliva. Archives of Oral Biology 48, 323–327. 
Creaser, C.S., Griffiths, J.R., Bramwell, C.J., Noreen, S., Hill, C. a., Thomas, C.L.P., 2004. 
Ion mobility spectrometry: a review. Part 1. Structural analysis by mobility measurement. 
The Analyst 129, 984. 
De Almeida, P. V., Gregio, A.M.T., Machado, M.A.N., De Lima, A.A.S., Azevedo, L.R., 
2008. Saliva composition and functions: a comprehensive review. Journal of Contemporary 
Dental Practice 9, 72–80. 
Dwivedi, P., Wu, P., Klopsch, S.J., Puzon, G.J., Xun, L., Hill, H.H., 2007. Metabolic 
profiling by ion mobility mass spectrometry (IMMS). Metabolomics 4, 63–80. 
Fonville, J.M., Richards, S.E., Barton, R.H., Boulange, C.L., Ebbels, T.M.D., Nicholson, J.K., 
Holmes, E., Dumas, M.-E., 2010. The evolution of partial least squares models and related 
chemometric approaches in metabonomics and metabolic phenotyping. Journal of 
Chemometrics 24, 636–649. 
Harry, E.L., Weston, D.J., Bristow, A.W.T., Wilson, I.D., Creaser, C.S., 2008. An approach 
to enhancing coverage of the urinary metabonome using liquid chromatography-ion mobility-
mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical 
and life sciences 871, 357–61. 
Humphrey, S.P., Williamson, R.T., 2001. A review of saliva: normal composition, flow, and 
function. The Journal of prosthetic dentistry 85, 162–9. 
Issaq, H.J., Abbott, E., Veenstra, T.D., 2008. Utility of separation science in metabolomic 
studies. Journal of separation science 31, 1936–47. 
Kanu, A.B., Dwivedi, P., Tam, M., Matz, L., Jr, H.H.H., 2008. SPECIAL FEATURE : Ion 
mobility – mass spectrometry. journal of Mass Spectrometry 43, 1–22. 
Lindon, J.C., Nicholson, J.K., 2008. Systems Biology Metabonomics. Nature 455, 1054–
1056. 
Nicholson, J.K., Lindon, J.C., Holmes, E., 1999. “Metabonomics”: understanding the 
metabolic responses of living systems to pathophysiological stimuli via multivariate 
statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189. 
Pink, R., Simek, J., Vondrakova, J., Faber, E., Michl, P., Pazdera, J., Indrak, K., 2009. Saliva 
as a diagnostic medium. Biomedical papers of the Medical Faculty of the University Palacký, 
Olomouc, Czechoslovakia 153, 103–110. 
Polson, C., Sarkar, P., Incledon, B., Raguvaran, V., Grant, R., 2003. Optimization of protein 
precipitation based upon effectiveness of protein removal and ionization effect in liquid 
chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical 
technologies in the biomedical and life sciences 785, 263–75. 
Shvartsburg, A. a, Smith, R.D., 2008. Fundamentals of traveling wave ion mobility 
spectrometry. Analytical chemistry 80, 9689–99. 
Swartz, M.E., 2005. UPLC TM : An Introduction and Review. Journal of Liquid 
Chromatography & Related Technologies 28, 1253–1263. 
Takeda, I., Stretch, C., Barnaby, P., Bhatnager, K., Rankin, K., Fu, H., Weljie, A., Jha, N., 
Slupsky, C., 2009. Understanding the human salivary metabolome. NMR in biomedicine 22, 
577–84. 
Van den Berg, R. a, Hoefsloot, H.C.J., Westerhuis, J. a, Smilde, A.K., Van der Werf, M.J., 
2006. Centering, scaling, and transformations: improving the biological information content 
of metabolomics data. BMC genomics 7, 142. 
Walsh, L.J., 2007. Clinical aspects of salivary biology for the dental clinician. International 
Dentistry South Africa (Australasian Edition) 2, 16–30. 
Want, E.J., Wilson, I.D., Gik, H., Theodoridis, G., Plumb, R.S., Shockcor, J., Holmes, E., 
Nicholson, J.K., Gika, H., 2010. Global metabolic profiling procedures for urine using 
UPLC–MS. Nature Protocols 5, 1005–1018. 
Wei, J., Xie, G., Zhou, Z., Shi, P., Qiu, Y., Zheng, X., Chen, T., Su, M., Zhao, A., Jia, W., 
2010. Salivary metabolite signatures of oral cancer and leukoplakia. International journal of 
cancer. 129, 2207–2217. 
Wishart, D.S., Jewison, T., Guo, A.C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, 
R., Aziat, F., Dong, E., Bouatra, S., Sinelnikov, I., Arndt, D., Xia, J., Liu, P., Yallou, F., 
Bjorndahl, T., Perez-Pineiro, R., Eisner, R., Allen, F., Neveu, V., Greiner, R., Scalbert, A., 
2013. HMDB 3.0--The Human Metabolome Database in 2013. Nucleic acids research 41, 
D801–7. 
Xiayan, L., Legido-Quigley, C., 2008. Advances in separation science applied to 
metabonomics. Electrophoresis 29, 3724–36. 
Zhang, A., Sun, H., Wang, P., Han, Y., Wang, X., 2012. Recent and potential developments 
of biofluid analyses in metabolomics. Journal of proteomics 75, 1079–88. 
  
  
7. LIST OF FIGURES 
Figure 1. UPLC-IM-MS metabonomic analysis of saliva extract. (a) UHPLC total ion 
chromatogram, (b) total ion mobility drift time plot summed over the entire chromatographic 
run, (c) retention time vs ion mobility drift time heatmap.  
Figure 2. UPLC-IM-MS analysis of saliva extract before and after optimisation of the T-
wave IM parameters. (a) Total ion mobility drift time plot (bins) prior to optimisation of IM 
parameters (b) Total ion mobility drift time plot (bins) after optimisation of IM parameters. 
Figure 3. UHPLC-IM-MS targeted analysis of L-phenylalanine (m/z 166.08) in a saliva 
extract (a) extracted ion chromatogram for L-phenylalanine (m/z 166.08±0.05), (b) mass 
spectrum at 1.21±0.03 min,  (c) selected ion mobility spectrum for L-phenylalanine (m/z 
166.08±0.05, 1.21±0.03 min), (d) mass spectrum at 1.21±0.03 min with ion mobility bins 64-
68 selected, showing spectral quality improvement. 
Figure 4. (a) Principal component analysis (PCA) of all saliva samples from the study 
(before-exercise, after-exercise and QC samples) Component 1 (14.17%) & Component 2 
(12.68%). (b) A supervised orthogonal partial least squares – discriminant analysis (OPLS-
DA) model, distinguishing between the two classes of samples (before-exercise and after-
exercise saliva samples) Component 1 (14.44%) & Component 2 (8.26%). 
Figure 5. Example raw data for selected potential biomarker ion m/z 100.07±0.02: (a) 
extracted ion chromatogram (EIC) showing change in intensity between before-exercise and 
after-exercise samples. Black trace denotes before-exercise and grey trace denotes after-
exercise EICs. (a) selected ion mobility spectrum for m/z 100.07±0.02 showing a single sharp 
peak, indicating the presence of a single m/z 100.07 species at retention time of 1.31 minutes. 
Figure 6. Identification of discriminant metabolite (a) extracted ion chromatogram for 
m/z 100.07 in saliva, (b) MS/MS spectrum for m/z 100.07 in saliva, (c) extracted ion 
chromatogram for δ-valerolactam standard, (d) MS/MS spectrum of δ-valerolactam standard, 
(e) selected ion mobility spectrum for m/z 100.07, (f) selected ion mobility spectrum for δ-
valerolactam. 






